



## SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

*Presented by*

**Yale School of Medicine, Human and Translational Immunology Program**

# **“CD47 mimicry and the battlefield of *Borrelia* vs. host immune modulation in Lyme disease”**

**Michal Tal, PhD**

**Postdoctoral Fellow, Institute for Stem Cell Biology and Regenerative Medicine  
Stanford University**

Date: February 19, 2019 at 4pm

Location: The Anlyan Center – TAC N203

Seminar Host: Dr. Aaron Ring

Course Director: Dr. Stephanie Eisenbarth and Dr. Carrie Lucas

*There is no corporate support for this activity. This activity is not supported by any educational grants.  
This course will fulfill the licensure requirement set forth by the State of Connecticut*

### **ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **TARGET AUDIENCE**

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

### **NEEDS ASSESSMENT**

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

### **LEARNING OBJECTIVES**

At the conclusion of this activity, participants will:

1. Learn about the CD47-SIRPα axis of immune modulation
2. Become aware of genetic polymorphisms and pathogen mimicry that impact CD47-SIRPα immune modulation
3. Learn about development of a flow cytometry based immune profiling assay of pathogen specific antibodies and how it reveals surprising immune responses to Lyme disease

### **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

### **FACULTY DISCLOSURES**

Michal Tal: Received stock from Acari Bio  
Stephanie Eisenbarth: None  
Carrie Lucas: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.